Unknown

Dataset Information

0

Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.


ABSTRACT: PURPOSE:While mutations in BRAF in metastatic colorectal cancer (mCRC) most commonly occur at the V600 amino acid, with the advent of next-generation sequencing, non-V600 BRAF mutations are increasingly identified in clinical practice. It is unclear whether these mutants, like BRAF V600E, confer resistance to anti-EGFR therapy. EXPERIMENTAL DESIGN:We conducted a multicenter pooled analysis of consecutive patients with non-V600 BRAF-mutated mCRCs identified between 2010 and 2017. Non-V600 BRAF mutations were divided into functional classes based on signaling mechanism and kinase activity: activating and RAS-independent (class 2) or kinase-impaired and RAS-dependent (class 3). RESULTS:Forty patients with oncogenic non-V600 BRAF-mutant mCRC received anti-EGFR antibody treatment [n = 12 (30%) class 2 and n = 28 (70%) class 3]. No significant differences in clinical characteristics were observed by mutation class. In contrast, while only 1 of 12 patients with class 2 BRAF mCRC responded, 14 of 28 patients with class 3 BRAF responded to anti-EGFR therapy (response rate, 8% and 50%, respectively, P = 0.02). Specifically, in first- or second-line, 1 of 6 (17%) patients with class 2 and 7 of 9 (78%) patients with class 3 BRAF mutants responded (P = 0.04). In third- or later-line, none of 6 patients with class 2 and 7 of 19 (37%) patients with class 3 BRAF mutants responded (P = 0.14). CONCLUSIONS:Response to EGFR antibody treatment in mCRCs with class 2 BRAF mutants is rare, while a large portion of CRCs with class 3 BRAF mutants respond. Patients with colorectal cancer with class 3 BRAF mutations should be considered for anti-EGFR antibody treatment.See related commentary by Fontana and Valeri, p. 6896.

SUBMITTER: Yaeger R 

PROVIDER: S-EPMC6891165 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.

Yaeger Rona R   Kotani Daisuke D   Mondaca Sebastián S   Parikh Aparna R AR   Bando Hideaki H   Van Seventer Emily E EE   Taniguchi Hiroya H   Zhao HuiYong H   Thant Claire N CN   de Stanchina Elisa E   Rosen Neal N   Corcoran Ryan B RB   Yoshino Takayuki T   Yao Zhan Z   Ebi Hiromichi H  

Clinical cancer research : an official journal of the American Association for Cancer Research 20190912 23


<h4>Purpose</h4>While mutations in BRAF in metastatic colorectal cancer (mCRC) most commonly occur at the V600 amino acid, with the advent of next-generation sequencing, non-V600 BRAF mutations are increasingly identified in clinical practice. It is unclear whether these mutants, like BRAF V600E, confer resistance to anti-EGFR therapy.<h4>Experimental design</h4>We conducted a multicenter pooled analysis of consecutive patients with non-V600 BRAF-mutated mCRCs identified between 2010 and 2017. N  ...[more]

Similar Datasets

| S-EPMC9556333 | biostudies-literature
| S-EPMC5546416 | biostudies-literature
| S-EPMC5941622 | biostudies-literature
| S-EPMC4669588 | biostudies-literature
| S-EPMC5560131 | biostudies-literature
| S-EPMC8073594 | biostudies-literature
| S-EPMC7579731 | biostudies-literature
| S-EPMC4891042 | biostudies-literature
| S-EPMC7244546 | biostudies-literature
| S-EPMC7529530 | biostudies-literature